SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma - Quaterly Results

26 Jul 2024 Evaluate
The sales surged to Rs. 10632.00 millions, up 25.61% for the June 2024 quarter as against Rs. 8464.30 millions during the corresponding quarter previous year.The Total Profit for the quarter ended June 2024 of Rs. 852.70 millions grew from Rs.-333.60 millionsOperating profit surged to 1883.90 millions from the corresponding previous quarter of 432.70 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202406 202306 % Var 202406 202306 % Var 202403 202303 % Var
Sales 10632.00 8464.30 25.61 10632.00 8464.30 25.61 43901.10 34432.20 27.50
Other Income 367.60 266.80 37.78 367.60 266.80 37.78 2020.60 3410.70 -40.76
PBIDT 1883.90 432.70 335.38 1883.90 432.70 335.38 8199.80 4386.00 86.95
Interest 248.80 338.00 -26.39 248.80 338.00 -26.39 1071.00 1158.70 -7.57
PBDT 1635.10 94.70 1626.61 1635.10 94.70 1626.61 7128.80 3157.70 125.76
Depreciation 518.50 503.70 2.94 518.50 503.70 2.94 2052.60 1920.80 6.86
PBT 1116.60 -409.00 -373.01 1116.60 -409.00 -373.01 5076.20 1236.90 310.40
TAX 263.90 -75.40 -450.00 263.90 -75.40 -450.00 1164.00 541.90 114.80
Deferred Tax -10.40 -75.40 -86.21 -10.40 -75.40 -86.21 39.20 154.20 -74.58
PAT 852.70 -333.60 -355.61 852.70 -333.60 -355.61 3912.20 695.00 462.91
Equity 13229.50 11933.20 10.86 13229.50 11933.20 10.86 13229.50 11933.20 10.86
PBIDTM(%) 17.72 5.11 246.61 17.72 5.11 246.61 18.68 12.74 46.63

Piramal Pharma Share Price

148.75 -0.15 (-0.10%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×